RAHWAY, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA in ...
Association of very deep prostate-specific antigen (PSA) decline with longer radiologic-progression-free survival (rPFS) in patients with metastatic castration-sensitive prostate cancer. This is an ...
AstraZeneca and Merck, known as MSD outside of the United States and Canada, today announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone has been approved in Japan for ...
The sNDA for LYNPARZA in combination with abiraterone and prednisone or prednisolone is based on the Phase 3 PROpel trial, results of which were published in NEJM Evidence in June 2022. The ...
Lynparza, Zytiga and prednisone led to improved progression-free survival and response rates in patients with metastatic prostate cancer. The drug combination of Lynparza (olaparib), Zytiga ...
Abiraterone acetate (AA) is a potent and selective inhibitor of CYP17, which is required for androgen biosynthesis in the testes, adrenal glands, and prostate tissue. This trial evaluated the efficacy ...
Treatment with Zytiga, prednisone and Erleada plus another treatment regimen improved prostate cancer outcomes and did not change health-related quality of life outcomes. Patients with prostate cancer ...
Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III ...
The phase 3 MAGNITUDE study assessed niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC with or without alterations in homologous recombination repair associated ...
The median OS was 28 months with abiraterone-prednisone, 37 months with olaparib alone, and 68 months with abiraterone-prednisone-olaparib. In patients with metastatic castration-resistant prostate ...
BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results